 Prometheus Biosciences Inc shares have rocketed more than 170 on positive results for its therapeutic candidate PRA023 in both its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. Prometheus is developing PRA023, a monoclonal antibody against cytokine TL1A, for the treatment of immune-mediated diseases including ulcerative colitis UC, Crohns disease CD, and systemic sclerosis-associated interstitial lung disease. 